Katherine Warren, MD
Dana-Farber Cancer Institute · National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Katherine Warren, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:24 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04341311 · Phase I Study of Marizomib + Panobinostat for Children With DIPGDana-Farber Cancer Institute · terminated · Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma, Pediatric Brainstem Gliosarcoma, Recurrent · principal investigator
- Ph2NCT00275002 · O6-Benzylguanine and Temozolomide in Treating Young Patients With Recurrent or Progressive Gliomas or Brain Stem TumorsNational Cancer Institute (NCI) · completed · Brain and Central Nervous System Tumors · study chair
- Ph1NCT00020150 · Temozolomide and O6-benzylguanine in Treating Children With Solid TumorsNational Cancer Institute (NCI) · completed · Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor · study chair
- Ph2NCT00019422 · Lobradimil and Carboplatin in Treating Children With Brain TumorsNational Cancer Institute (NCI) · completed · Brain and Central Nervous System Tumors · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in diffuse midline glioma (dipg).